济川药业
(600566)
| 流通市值：255.88亿 | | | 总市值：256.74亿 |
| 流通股本：9.18亿 | | | 总股本：9.21亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,932,057,245.53 | 2,748,717,966.21 | 1,525,389,316.3 | 8,016,894,756.63 |
| 营业收入 | 3,932,057,245.53 | 2,748,717,966.21 | 1,525,389,316.3 | 8,016,894,756.63 |
| 二、营业总成本 | 2,887,618,682.39 | 2,042,988,755.57 | 1,106,091,598.54 | 5,388,666,480.38 |
| 营业成本 | 932,609,817.16 | 668,448,217.04 | 347,010,714.96 | 1,663,540,786.59 |
| 税金及附加 | 75,327,723.7 | 53,915,862.37 | 28,352,466.9 | 134,385,142.83 |
| 销售费用 | 1,338,590,972.63 | 976,858,157.57 | 557,671,736.88 | 2,954,132,882.49 |
| 管理费用 | 323,849,037.19 | 209,600,908.03 | 101,924,935.8 | 432,654,677.67 |
| 研发费用 | 271,853,927.95 | 189,893,896.33 | 100,945,084.37 | 444,781,764.51 |
| 财务费用 | -54,612,796.24 | -55,728,285.77 | -29,813,340.37 | -240,828,773.71 |
| 其中:利息费用 | 9,411,741.46 | 7,057,473.19 | 3,508,802.64 | 27,273,290.37 |
| 其中:利息收入 | 64,747,386.59 | 63,350,787.56 | 33,626,362.84 | 269,224,895.33 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 17,463,116.07 | -32,509,512.31 | 11,969,723.03 | 99,202,006.27 |
| 加:投资收益 | 156,700,654.11 | 131,621,780.6 | 28,673,815.84 | 83,540,174.24 |
| 资产处置收益 | 81,330.68 | 68,411.54 | - | 197,641.88 |
| 资产减值损失(新) | -1,140,852.47 | -1,140,852.47 | 1,202.98 | -2,881,730.82 |
| 信用减值损失(新) | 22,621,190.37 | 20,954,411.68 | 37,363,496.91 | 22,258,137.62 |
| 其他收益 | 14,964,351.52 | 8,704,866.43 | 5,018,401.98 | 32,345,111 |
| 四、营业利润 | 1,255,128,353.42 | 833,428,316.11 | 502,324,358.5 | 2,862,889,616.44 |
| 加:营业外收入 | 17,768,694.95 | 16,707,318.28 | 12,738,381.35 | 116,799,700.02 |
| 减:营业外支出 | 12,490,833.61 | 1,092,800.86 | 393,735.39 | 1,443,057.47 |
| 五、利润总额 | 1,260,406,214.76 | 849,042,833.53 | 514,669,004.46 | 2,978,246,258.99 |
| 减:所得税费用 | 236,289,212.9 | 123,756,924.63 | 73,376,337.8 | 441,539,927.5 |
| 六、净利润 | 1,024,117,001.86 | 725,285,908.9 | 441,292,666.66 | 2,536,706,331.49 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 1,024,117,001.86 | 725,285,908.9 | 441,292,666.66 | 2,536,706,331.49 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 1,022,463,426.87 | 724,364,011.18 | 440,335,904.83 | 2,531,554,060.02 |
| 少数股东损益 | 1,653,574.99 | 921,897.72 | 956,761.83 | 5,152,271.47 |
| 扣除非经常损益后的净利润 | 859,256,809.58 | 620,630,136.55 | 392,137,823.14 | 2,265,964,029.11 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.11 | 0.78 | 0.48 | 2.76 |
| (二)稀释每股收益 | 1.11 | 0.78 | 0.48 | 2.76 |
| 九、综合收益总额 | 1,024,117,001.86 | 725,285,908.9 | 441,292,666.66 | 2,536,706,331.49 |
| 归属于母公司股东的综合收益总额 | 1,022,463,426.87 | 724,364,011.18 | 440,335,904.83 | 2,531,554,060.02 |
| 归属于少数股东的综合收益总额 | 1,653,574.99 | 921,897.72 | 956,761.83 | 5,152,271.47 |
| 公告日期 | 2025-10-28 | 2025-08-23 | 2025-04-26 | 2025-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |